Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Lineage Cell Therapeutics Inc’s current trading price is -56.52% away from its 52-week high, while its distance from the 52-week low is -8.68%. The stock’s price range during this period has varied between $0.77 and $1.61. The company, active in the Healthcare sector, saw a trading volume of around 4.13 million for the day, considerably higher average daily volume of 0.42 million observed over the last three months.
Lineage Cell Therapeutics Inc had a pretty Dodgy run when it comes to the market performance. Over the past year, the company’s stock reached a high of $1.61 on 03/28/24, while the lowest price during the same period was $0.77 on 11/20/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly decline of -21.53% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 132.19M and boasts a workforce of 75 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.9069, with a change in price of -0.2475. Similarly, Lineage Cell Therapeutics Inc recorded 519,970 in trading volume during the last 100 days, posting a change of -25.94%.
How LCTX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.02.
LCTX Stock Stochastic Average
As of today, the raw stochastic average of Lineage Cell Therapeutics Inc over the last 50 days is at 2.44%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 2.44%. Further, the company’s Stochastic %K and %D values for the last 20 days were 36.58% and 42.91%, respectively.
LCTX Stock Price Performance Analysis
Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -35.78%. However, over the past six months, we’ve seen a stronger performance of -33.33%. The price of LCTX leaped by -20.97% over the last 30 days. And in the last five days, it has fallen by -23.33%.
